par Van Els, Cecile A C M C.A.C.M.;Corbiere, Véronique 
;Smits, Kaatje ;van Gaans-van den Brink, Jacqueline A M;Poelen, Martien C M;Mascart, Françoise ;Meiring, Hugo H.D.;Locht, Camille
Référence Frontiers in immunology, 5, AUG, page (1-10), Article 361
Publication Publié, 2014
;Smits, Kaatje ;van Gaans-van den Brink, Jacqueline A M;Poelen, Martien C M;Mascart, Françoise ;Meiring, Hugo H.D.;Locht, Camille Référence Frontiers in immunology, 5, AUG, page (1-10), Article 361
Publication Publié, 2014
Article révisé par les pairs
| Résumé : | CD4+ T cells are prominent effector cells in controlling Mycobacterium tuberculosis (Mtb) infection but may also contribute to immunopathology. Studies probing the CD4+ T cell response from individuals latently infected with Mtb or patients with active tuberculosis using either small or proteome-wide antigen screens so far revealed a multi-antigenic, yet mostly invariable repertoire of immunogenic Mtb proteins. Recent developments in mass spectrometry-based proteomics have highlighted the occurrence of numerous types of post-translational modifications (PTMs) in proteomes of prokaryotes, including Mtb. The well-known PTMs in Mtb are glycosylation, lipidation, or phosphorylation, known regulators of protein function or compartmentalization. Other PTMs include methylation, acetylation, and pupylation, involved in protein stability. While all PTMs add variability to the Mtb proteome, relatively little is understood about their role in the anti-Mtb immune responses. Here,we reviewMtb protein PTMs and methods to assess their role in protective immunity against Mtb. © 2014 van Els, Corbière, Smits, vanGaans-van den Brink, Poelen, Mascart, Meiring and Locht. |
